Brainever

Description

Brainever develops hEN1 and hOTX2 homeoprotein drug candidates intended to limit neurodegenerative disease progression by preventing neuronal loss and altering surviving neuron physiology for ALS, Parkinson’s disease, and retinal diseases.

Brainever is located in the Paris ecosystem.

Related

• Herantis PharmaHerantis Pharma develops disease-modifying therapies designed to stop or reverse progression of neurodegenerative diseases, applying drug…
• BioArcticBioArctic develops therapeutics and related technologies for neurodegenerative disorders, focusing on disease-modifying treatments and…
• Anacalypsis TherapeuticsAnacalypsis Therapeutics creates precision gene- and pathway-based therapeutic strategies, biomarkers, and genetically linked targets to…
• Qubit PharmaceuticalsQubit Pharmaceuticals develops quantum- and AI-driven molecular modeling platforms and drug discovery tools used to design novel drug…
• Breye TherapeuticsBreye Therapeutics develops orally administered ophthalmology drugs, including danegaptide and P2X7 receptor antagonists, to treat retinal…
• ResQ BiotechResQ Biotech builds a living-cell discovery platform that biosynthesizes and functionally screens ultra-large libraries to identify…
• RobeautéRobeauté develops a brain microrobotic platform for neuro-interventions, using rice-sized microrobots and related infrastructure to better…
• OsivaxOsivax develops oligoDOM self-assembling nanoparticle vaccines that activate T-cell and B-cell immunity for broader protection against…
• ScientaLabScientaLab develops a foundation model that predicts human immune response in immunology and inflammation, using multi-disease,…